Jan 24 (Reuters) - Eli Lilly and Co said on Tuesday it plans to invest an additional $450 million to expand its manufacturing capacity at the Research Triangle Park facility in North Carolina to support increased demand for its diabetes drugs.

Since 2020, the drugmaker has committed around $4 billion to new manufacturing facilities in North Carolina, including $1.7 billion for the development and expansion of its site at Research Triangle Park. (Reporting by Leroy Leo in Bengaluru; Editing by Sherry Jacob-Phillips)